Matches in SemOpenAlex for { <https://semopenalex.org/work/W1671254148> ?p ?o ?g. }
- W1671254148 endingPage "643" @default.
- W1671254148 startingPage "635" @default.
- W1671254148 abstract "A phase 1 study with carfilzomib and vorinostat was conducted in 20 B-cell lymphoma patients. Vorinostat was given orally twice daily on days 1, 2, 3, 8, 9, 10, 15, 16, and 17 followed by carfilzomib (given as a 30-min infusion) on days 1, 2, 8, 9, 15, and 16. A treatment cycle was 28 days. Dose escalation initially followed a standard 3 + 3 design, but adapted a more conservative accrual rule following dose de-escalation. The maximum tolerated dose was 20 mg/m2 carfilzomib and 100 mg vorinostat (twice daily). The dose-limiting toxicities were grade 3 pneumonitis, hyponatremia, and febrile neutropenia. One patient had a partial response and two patients had stable disease. Correlative studies showed a decrease in NF-κB activation and an increase in Bim levels in some patients, but these changes did not correlate with clinical response." @default.
- W1671254148 created "2016-06-24" @default.
- W1671254148 creator A5009574158 @default.
- W1671254148 creator A5009580386 @default.
- W1671254148 creator A5010912685 @default.
- W1671254148 creator A5013173470 @default.
- W1671254148 creator A5038526399 @default.
- W1671254148 creator A5040163182 @default.
- W1671254148 creator A5047406424 @default.
- W1671254148 creator A5055100327 @default.
- W1671254148 creator A5057507865 @default.
- W1671254148 creator A5061036144 @default.
- W1671254148 creator A5061640981 @default.
- W1671254148 creator A5074048193 @default.
- W1671254148 creator A5074375413 @default.
- W1671254148 creator A5075559357 @default.
- W1671254148 creator A5078369490 @default.
- W1671254148 creator A5078600949 @default.
- W1671254148 creator A5080689260 @default.
- W1671254148 creator A5086403929 @default.
- W1671254148 creator A5089845667 @default.
- W1671254148 creator A5091632652 @default.
- W1671254148 date "2015-10-12" @default.
- W1671254148 modified "2023-09-24" @default.
- W1671254148 title "Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas" @default.
- W1671254148 cites W1812576394 @default.
- W1671254148 cites W1905474624 @default.
- W1671254148 cites W1913222118 @default.
- W1671254148 cites W1972887455 @default.
- W1671254148 cites W1976678451 @default.
- W1671254148 cites W1979358785 @default.
- W1671254148 cites W2009823821 @default.
- W1671254148 cites W2016742872 @default.
- W1671254148 cites W2023457562 @default.
- W1671254148 cites W2027092131 @default.
- W1671254148 cites W2032167699 @default.
- W1671254148 cites W2037920224 @default.
- W1671254148 cites W2040893174 @default.
- W1671254148 cites W2047542386 @default.
- W1671254148 cites W2050115670 @default.
- W1671254148 cites W2051503798 @default.
- W1671254148 cites W2060707415 @default.
- W1671254148 cites W2066264051 @default.
- W1671254148 cites W2071115015 @default.
- W1671254148 cites W2074519099 @default.
- W1671254148 cites W2085103698 @default.
- W1671254148 cites W2096065464 @default.
- W1671254148 cites W2096367061 @default.
- W1671254148 cites W2097856894 @default.
- W1671254148 cites W2116851173 @default.
- W1671254148 cites W2125877270 @default.
- W1671254148 cites W2129890171 @default.
- W1671254148 cites W2133024348 @default.
- W1671254148 cites W2133201432 @default.
- W1671254148 cites W2135619784 @default.
- W1671254148 cites W2136905052 @default.
- W1671254148 cites W2141920998 @default.
- W1671254148 cites W2143161378 @default.
- W1671254148 cites W2147422161 @default.
- W1671254148 cites W2149386327 @default.
- W1671254148 cites W2151963356 @default.
- W1671254148 cites W2152694994 @default.
- W1671254148 cites W2160788856 @default.
- W1671254148 cites W2168980644 @default.
- W1671254148 cites W2292115641 @default.
- W1671254148 cites W2473589544 @default.
- W1671254148 cites W3167169307 @default.
- W1671254148 cites W4248583329 @default.
- W1671254148 cites W89645637 @default.
- W1671254148 doi "https://doi.org/10.3109/10428194.2015.1075019" @default.
- W1671254148 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4798896" @default.
- W1671254148 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26284612" @default.
- W1671254148 hasPublicationYear "2015" @default.
- W1671254148 type Work @default.
- W1671254148 sameAs 1671254148 @default.
- W1671254148 citedByCount "17" @default.
- W1671254148 countsByYear W16712541482016 @default.
- W1671254148 countsByYear W16712541482017 @default.
- W1671254148 countsByYear W16712541482018 @default.
- W1671254148 countsByYear W16712541482019 @default.
- W1671254148 countsByYear W16712541482020 @default.
- W1671254148 countsByYear W16712541482021 @default.
- W1671254148 countsByYear W16712541482022 @default.
- W1671254148 crossrefType "journal-article" @default.
- W1671254148 hasAuthorship W1671254148A5009574158 @default.
- W1671254148 hasAuthorship W1671254148A5009580386 @default.
- W1671254148 hasAuthorship W1671254148A5010912685 @default.
- W1671254148 hasAuthorship W1671254148A5013173470 @default.
- W1671254148 hasAuthorship W1671254148A5038526399 @default.
- W1671254148 hasAuthorship W1671254148A5040163182 @default.
- W1671254148 hasAuthorship W1671254148A5047406424 @default.
- W1671254148 hasAuthorship W1671254148A5055100327 @default.
- W1671254148 hasAuthorship W1671254148A5057507865 @default.
- W1671254148 hasAuthorship W1671254148A5061036144 @default.
- W1671254148 hasAuthorship W1671254148A5061640981 @default.
- W1671254148 hasAuthorship W1671254148A5074048193 @default.
- W1671254148 hasAuthorship W1671254148A5074375413 @default.
- W1671254148 hasAuthorship W1671254148A5075559357 @default.